Interferon alfa-2b is used as maintenance treatment in patients with multiple myeloma.' Although renal toxicity is rare, mild proteinuria is common.2 We present the case of a patient who developed acute renal failure during treatment with recombinant interferon alfa-2b. A 49 year old woman was admitted with a week's history of nausea, vomiting, and declining urinary output. Two years previously an IgG K multiple myeloma had been diagnosed. Ten months before admission maintenance treatment with recombinant interferon alfa-2b (intron A) 3 MU was started subcutaneously thrice weekly. She took additionally only ferrous sulphate and vitamin B complex. On admission she was pale and apyrexial, with a blood pressure of 120/70 mmHg, a sinus tachycardia of 100 beats/min, and a central venous pressure of 1 mm H20.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.